美他环素联合利福平治疗难治性布鲁菌病的临床疗效观察  

The clinical efficacy of metacydine and rifampicin in patients with intractable Brucellosis

作　　者：王万鹏[1] 谭炳芹[1] 闫振武[1] 肖婷[1] 陈建红[1] 

机构地区：[1]山东省潍坊市人民医院感染性疾病科,潍坊261041

出　　处：《中华地方病学杂志》2018年第1期73-76,共4页Chinese Journal of Endemiology

摘　　要：目的分析美他环素联合利福平治疗难治性布鲁菌病的临床疗效，为临床治疗提供依据。方法2013年2月至2016年2月，在潍坊市人民医院感染性疾病科就诊患者中，以诊断为难治性布鲁菌病的65例患者作为研究对象，分为2组，治疗组33例，给予美他环素联合利福平治疗；对照组32例，给予多西环素、利福平联合左氧氟沙星治疗，6周为治疗终点。观察2组患者治疗效果及不良反应情况，并进行统计分析。结果治疗组有效率（96．97％，32／33）明显高于对照组（75．00％，24／32，x2=4．86，P〈0．05）。对照组胃肠道反应发生率（37．50％，12／32）明显高于治疗组（15．15％，5／33，x2=4．20，P〈0．05），2组患者肝功能损害、皮疹和白细胞减少的发生率无明显差异（x2=0．49、0．00、1．62，P均〉0．05）。结论美他环素联合利福平治疗难治性布鲁菌病安全性好，有效率高，值得临床推广。Objective To analyze the clinical efficacy of metacycline and rifampicin in the patients with refractory brucellosis, and to provide evidence for clinical treatment. Methods From February 2013 to February 2016, sixty-five patients diagnosed refractory brucellosis at the Department of Infectious Diseases, Weifang People＇s Hospital were enrolled in this study. They were randomly divided into two groups, treatment group （33 cases） and control group （32 cases）. Patients of treatment group were treated with metacycline joint rifampicin, and control group was treated with doxycycline hyclate, rifampicin and levofloxacin. After treatment for six weeks, the clinical efficacy and adverse reactions were observed and data were analyzed. Results The effective rate in treatment group （96.97%, 32/33） was significantly higher than that in control group （75.00%, 24/32, X2 = 4.86, P 〈 0.05）. The incidence of gastrointestinal reactions in control group （37.50%, 12/32） was much higher than that in treatment group （15.15%, 5/33, X2 = 4.20, P 〈 0.05）. There were no significant differences between the two groups in the incidence of liver damage, skin rash and leukopenia （X2 = 0.49, 0.00, 1.62, P 〉 0.05）. Conclusion The combined treatment metacycline and rifampicin is safe with high efficiency for patients with refractory brucellosis, and is worthy to be promoted.

关 键 词：美他环素 利福平 布鲁菌病 临床疗效 

分 类 号：R516.7[医药卫生—内科学]